Ikena Oncology Inc
NASDAQ:IKNA
Intrinsic Value
Ikena Oncology, Inc. is a clinical stage biotechnology company. [ Read More ]
The intrinsic value of one IKNA stock under the Base Case scenario is 0.91 USD. Compared to the current market price of 1.29 USD, Ikena Oncology Inc is Overvalued by 29%.
Valuation Backtest
Ikena Oncology Inc
Run backtest to discover the historical profit from buying and selling IKNA stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Ikena Oncology Inc
Current Assets | 178.7m |
Cash & Short-Term Investments | 175.5m |
Other Current Assets | 3.2m |
Non-Current Assets | 13.4m |
PP&E | 8m |
Other Non-Current Assets | 5.4m |
Current Liabilities | 14.2m |
Accounts Payable | 2.1m |
Accrued Liabilities | 12.1m |
Other Current Liabilities | 85k |
Non-Current Liabilities | 8.1m |
Other Non-Current Liabilities | 8.1m |
Earnings Waterfall
Ikena Oncology Inc
Revenue
|
9.2m
USD
|
Operating Expenses
|
-84.6m
USD
|
Operating Income
|
-75.4m
USD
|
Other Expenses
|
7.3m
USD
|
Net Income
|
-68.2m
USD
|
Free Cash Flow Analysis
Ikena Oncology Inc
IKNA Profitability Score
Profitability Due Diligence
Ikena Oncology Inc's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
Score
Ikena Oncology Inc's profitability score is 14/100. The higher the profitability score, the more profitable the company is.
IKNA Solvency Score
Solvency Due Diligence
Ikena Oncology Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Ikena Oncology Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IKNA Price Targets Summary
Ikena Oncology Inc
According to Wall Street analysts, the average 1-year price target for IKNA is 8.33 USD .
Ownership
IKNA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
IKNA Price
Ikena Oncology Inc
Average Annual Return | -47.38% |
Standard Deviation of Annual Returns | 47.56% |
Max Drawdown | -96% |
Market Capitalization | 62.3m USD |
Shares Outstanding | 48 260 000 |
Percentage of Shares Shorted | 3.35% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Ikena Oncology, Inc. is a clinical stage biotechnology company. The company is headquartered in Boston, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2021-03-26. The firm is focused on developing cancer therapies targeting signaling pathways that drive the formation and spread of cancer. Its oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain (TEAD), transcription factor in the Hippo signaling pathway. The company intends to pursue clinical development of IK-930 across a range of tumor types with known Hippo pathway mutations. Its oncology programs also include extracellular signal-related kinase 5 (ERK5) inhibitor / RAS Signaling Pathway inhibitor program, RAS Pathway discovery programs, Tumor Microenvironment Programs, IK-175, IK-412 and IK-007. The firm is developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway. The company also has early stage discovery programs in targeted oncology in the RAS pathway.
Contact
IPO
Employees
Officers
The intrinsic value of one IKNA stock under the Base Case scenario is 0.91 USD.
Compared to the current market price of 1.29 USD, Ikena Oncology Inc is Overvalued by 29%.